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549 A LONGITUDINAL STUDY TO ASSESS THE FUNCTIONAL
CHANGES CAUSED BY HYALURONIC ACID (HA) INJECTION
(DUROLANE) IN OSTEOARTHRITIS KNEES USING
VIBRATION ANALYSIS AND MAGNETIC RESONANCE
IMAGING
S. Salari1, H. Wu1, C. Webber1, C.O. Fuentes2, R.A. Ogilvie2,
R. Bobba2, J.F. MacGregor1, J.D. Adachi1. 1McMaster University,
Hamilton, ON, CANADA, 2Hamilton Health Sciences, Hamilton, ON,
CANADA
Purpose: The purpose of this longitudinal study was to assess the
functional changes caused by HA acid injection into the knees of patients
suffering from osteoarthritis (OA). Our hypothesis in this ongoing research
project is that Durolane, a type of synthesized HA, which acts as a viscous
lubricating ﬂuid would improve the mechanical functionality of the joint
and reduce friction between the articulating surfaces of the knee. This
improvement would in turn result in less vibration generated by the knee
during motion.
Methods: 11 patients, diagnosed with severe OA, were recruited from
local rheumatology clinics. Before the injection, each patient was tested
with a vibration analysis device. The patient also underwent a full anatom-
ical MRI scan of the knee. In addition, patients were asked to complete
the WOMAC pain, stiffness and functionality assessment questionnaires.
After the baseline vibration recording and MRI of the involved knee,
patients were injected with 3ml of Durolane. After the injection, the patient
was asked to do some mild exercise, for 10 to 15 minutes and a second
vibration test was performed in the injected knee. The patient was asked
to return for follow-up studies one week, 5 weeks, 9 weeks and 13 weeks
after the injection. At each follow-up appointment the injected knee was
tested again with sound analysis and the patient was asked to ﬁll out
the WOMAC questionnaire. At the ﬁnal appointment, the MRI scan of the
injected knee was repeated.
Analysis: As reported elsewhere, we have developed a vibration based
statistical model of the functionality of the articulating surfaces of the knee
in healthy and OA patients. By projecting vibration data from the patients
injected with HA into this statistical model, we expect to identify trends
of improvement after the injection followed by a gradual worsening of the
knee functionality as time elapses and the injection effects disappear.
Results: To date we have performed baseline and early follow-up
measurements in 4 patients. Eleven patients who will be receiving the
Durolane injection have been recruited. Figure 1 shows the hypothesized
results for 1 patient superimposed upon a vibration test report. We
anticipate that such results will allow an objective assessment of the
effectiveness of therapy in each patient.
Figure 1: Hypothesized trajectory of patient’s knee smoothness before
and after receiving Durolane injection
Conclusions: We are hoping that if we get promising results from our
current research, the technique can be used as a potential tool to assess
the functionality of the joint and for monitoring treatment effectiveness.
550 THERAPEUTIC PAIN MODULATION OF OSTEOARTHRITIS
OF THE L-S SPINE ASSOCIATED WITH DEGENERATIVE
LUMBAR DISC DISEASE, CHRONIC LUMBAR
RADICULOPATHY, MUSCLE SPASM AND FIBROMYALGIA
J.P. Figueroa. Harrington Memorial Hospital, Southbridge, MA, USA
Purpose:Osteoarthritis (OA) of the LS spine tends to present with degen-
erative lumbar disc disease (DDD), chronic lumbar radiculopathy (CLR),
muscle spasm (M-SP) and ﬁbromyalgia (FIBRO). Optimal treatment of
this condition can necessitate multiple medications sequenced for the
best clinical effect.
Methods: Traditional medical training has been to avoid opiates even if
the patient’s pain level is moderate to severe and even if basic activities
of daily living remain signiﬁcantly impaired. This is for reasons not only of
narcotic dependency and constipation but also for sleep fragmentation,
anxiety and depression as well. In these instances the patient may ex-
perience unrelenting pain and have profound disturbances on their sleep
cycle. Not untypically the continuous disturbances in their sleep cycle
can be associated with the appearance of FIBRO. Fibrositic tenderpoint’s
located in the paralumbar and sacroiliac regions will further compound
the low back pain that the patient is experiencing.
More recently there has been described an improvement in both the
quality and duration of sleep associated with the use of long-acting
opiates for chronic low back pain associated with osteoarthritis. These
patients can typically experience FIBRO along with the associated chronic
sleep disturbance of their low back pain. The intensity of this pain
frequently is such that it will not allow sufﬁcient pharmacologic sleep
augmentation to occur. This results in less than desired decrease in
tenderpoint discomfort. Once the appropriately titrated dose of long-acting
opiate has been achieved then typically a formulation such as branded
tizanidine capsules can have a very beneﬁcial effect on the patient’s
sleep. Only then will there occur a reduction in ﬁbrositic tenderpoint
discomfort as well as other associated ﬁbromyalgia related symptoms
such as fatigue, stiffness, headache and depression.
Interestingly, ulterior pain modulation of the lower back occurs with the
diclofenac patch 1.3% (applied to the lower back of the aforementioned
patients). There occurs a level of pain reduction that is beyond that which
would be expected with typical oral NSAID use. While the diclofenac patch
has been approved for use in low back strain it has not been investigated
for complex clinical low back pain conditions as presented.
Results: The clinical case presentations demonstrate the beneﬁt of ap-
propriately titrated long acting opiates. Also seen is an additional degree
of analgesic relief with the diclofenac patch 1.3%. Once pain has been
adequately modulated only then can sleep augmentation be successfully
introduced with tizanidine capsules to treat co existing FIBRO. The clinical
result is a much more optimally controlled level of pain and a higher level
of function.
Conclusions: Just as in the treatment of hypertension and cancer,
typically the treatment of low back pain associated with OA, DDD, M-SP
and FIBRO may require the use of multiple medications. When traditional
treatment methods fail to arrive at an acceptable clinical result then
appropriately titrated opiates can be effective. Non narcotic diclofenac
patches offer additional clinical beneﬁt. Once pain modulation is ade-
quately accomplished, tizanidine capsules can be used to effectively treat
coexisting ﬁbromyalgia.
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551 TREATMENT OF CARTILAGE DEFECTS IN THE KNEE
USING ALGINATE BEADS CONTAINING HUMAN MATURE
ALLOGENIC CHONDROCYTES
K.F. Almqvist Sr, A.A. Dhollander Jr., P.C. Verdonk Jr., R. Forsyth Sr.,
R. Verdonk Sr., G. Verbruggen Sr.. Ghent University Hospital, Gent,
BELGIUM
Purpose: To determine whether the implantation of alginate beads con-
taining human mature allogenic chondrocytes in symptomatic cartilage
defects of the knee results in structural regeneration of the joint surface
and improves clinical outcome.
Methods: A biodegradable, alginate-based biocompatible scaffold con-
taining human mature allogenic chondrocytes was used for the treatment
of chondral and osteochondral lesions in the knee. Twenty-one patients
were clinically prospectively evaluated with use of the Western Ontario
and McMaster Universities Osteoarthritis Index (WOMAC) and a Visual
Analogue Scale (VAS) for pain preoperatively and at 3, 6, 9 and 12 months
of follow-up. Of the 21 patients, 13 had consented to the taking of a biopsy
for investigative purposes from the area of implantation at 12 months of
follow-up, allowing histological assessment of the repair tissue.
Results: A statistically signiﬁcant clinical improvement became apparent
after 6 months and patients continued to improve during the 12 months
of follow-up. Adverse reactions to the alginate/ﬁbrin matrix seeded with
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the allogenic cartilage cells were not observed. Histological analysis of
the biopsy specimens rated the repair tissue as hyaline-like in 15.3%, as
mixed tissue in 46.2%, as ﬁbrocartilage in 30.8% and as ﬁbrous in 7.7%.
Conclusions: The results of this pilot study show that the alginate-
based scaffold containing mature human allogenic chondrocytes provides
clinical and histological outcomes equal to those of other cartilage repair
techniques.
552 MUSCLE STRENGTH AND FUNCTIONAL PERFORMANCE
IN PATIENTS WITH ANTERIOR CRUCIATE LIGAMENT
INJURY TREATED WITH TRAINING AND SURGICAL
RECONSTRUCTION OR TRAINING ONLY: A 2 TO 5-YEAR
FOLLOW-UP
E. Ageberg1, R. Thomee´2, C. Neeter2, K. Gra¨vare-Silbernagel2,
E.M. Roos3. 1Dept of Orthopedics, Lund University, Lund, SWEDEN,
2Lundberg Laboratory of Orthopaedic Research, Go¨teborg University,
Go¨teborg, SWEDEN, 3Sports Science and Clinical Biomechanics,
Odense M, DENMARK
Purpose: To study muscle strength and functional performance in pa-
tients with anterior cruciate ligament (ACL) injury with or without surgical
reconstruction 2 to 5 years after injury. Good muscle function is important
in preventing early-onset osteoarthritis (OA), but the role of reconstructive
surgery in restoring muscle function is unclear.
Methods: 54 patients (mean age at follow up 30 years, range 20−39,
28% women), out of 121 patients with ACL injury included in a randomized
controlled trial on training and surgical reconstruction vs. training only
(the KANON study, ISRCTN84752559), were assessed 3 years (SD 0.9)
after injury with reliable, valid and responsive test batteries for strength
(knee extension, knee ﬂexion, leg press) and hop performance (vertical
jump, one-leg hop, side hop). The Limb Symmetry Index (LSI, injured leg
divided by uninjured and multiplied by 100) value, and absolute values
were used for comparisons between groups (analysis of variance). An
LSI 90% was considered normal.
Results: There were no differences between the surgical and the non-
surgical treatment groups in muscle strength or functional performance.
Between 44% and 89% of the subjects had normal muscle function in
the single tests, and between 44% and 56% had normal function in the
test batteries.
Conclusions: The lack of differences between patients treated with
training and surgical reconstruction or training only, indicates that re-
constructive surgery is not a prerequisite for restoring muscle function.
Abnormal muscle function, found in about one third or more of the
patients, may be a predictor of future knee OA.
553 BIOCOMPATIBLE PHOSPHOLIPID POLYMER GRAFTING ON
LINER SURFACE OF ARTIFICIAL HIP JOINTS ENHANCES
THE WEAR RESISTANCE INDEPENDENTLY OF LINER
CROSS-LINKING OR FEMORAL HEAD MATERIAL
T. Moro, Y. Takatori, M. Kyomoto, K. Ishihara, K. Nakamura,
H. Kawaguchi. The University of Tokyo, Tokyo, JAPAN
Purpose: Artiﬁcial joint replacement is approved by OARSI guidelines as
the treatment of hip and knee osteoarthritis (OA) with the highest recom-
mended strength and cost-effectiveness (OA&C 2007, 2008). However,
the aseptic loosening induced by wear particles from the polyethylene
(PE) liner remains as the fatal problem limiting their longevity and clinical
success, despite contraptions such as cross-linking of the liner and
changes of the femoral head material. We have developed a novel PE
liner with the surface graft of a biocompatible phospholipids polymer,
2-methacryloyloxyethyl phosphorylcholine (MPC), and reported that this
dramatically decreased the wear production in a hip joint simulator
(Nature Mat 2004). This study compared the MPC effect with those of
the liner cross-linking and the femoral head material.
Methods: We prepared PE liners with or without cross-linking (PE &
CLPE) and photoinduced grafting of MPC onto the surfaces (MPC-PE &
MPC-CLPE). The hydrophilicity of the surface was determined by the
contact angle of a water drop, and the friction torque was measured
against cobalt-chromium alloy (Co-Cr) or alumina ceramic femoral head.
The wear amount was measured as the loss of the liner weight during
5×106 cycles of loading (comparable to 5 to 10 years of physical walking)
in the hip joint simulator. The surfaces of the liners and femoral heads,
as well as the wear particles in the lubricant were analyzed by confocal
scanning laser and electron microscopies, three-dimensional morphom-
etry, and XPS spectroscopy.
Results: The MPC grafting increased hydrophilicity to 5−6 fold and
decreased friction torque to 1/5−1/10, independently of the liner cross-
linking or the femoral head material. Cross-linking by itself altered neither
of them. The loss of liner weight (mg) after 5×106 cycles of loading in the
hip simulator was PE/Co-Cr = 99.6, CLPE/Co-Cr = 18.9, CLPE/alumina =
14.8, MPC-PE/Co-Cr = −5.9, MPC-CLPE/Co-Cr = −6.9, and MPC-
CLPE/alumina = −6.4, indicating that cross-linking caused a signiﬁcant
decrease of wear amount while the femoral head material little affected
it. The MPC grafting abrogated the wear amount, independently of the
liner cross-linking or the femoral head material. The gain of weight in the
MPC-grafted liners was conﬁrmed to be due to water absorption, since it
was similarly seen in all liners with and without MPC grafting during soak
without motion in the lubricant. The suppressions of the wear on the
liner surface and the particle amount in the lubricant by the MPC grafting
were much stronger than those by the cross-linking, independently of the
femoral head material. Interestingly, the particle size from the CLPE liner
was around 0.1mm, while that from PE or MPC-grafted liners was around
10mm.
Conclusions: The MPC grafting increased the surface lubricity and
diminished the wear production, independently of the liner cross-linking or
the femoral head material. In addition, we previously reported that MPC-
grafted wear particles, even if produced, are biologically inert with respect
to phagocytosis by macrophages and subsequent bone resorption. Al-
though cross-linking also suppressed the wear, it did not alter the surface
lubricity but produced submicrometer-sized particles which are known
to induce more catabolic responses above than larger particles. Taken
together, we believe that the MPC grafting surpasses the cross-linking
of the liner and the change of the femoral head materials in extending
longevity of artiﬁcial hip joints. A large-scale clinical trial is now underway.
554 VARIABILITY IN DISEASE SEVERITY AT THE TIME OF
PRIMARY HIP REPLACEMENT FOR OSTEOARTHRITIS
P.A. Dieppe1, A. Judge2, S. Williams2, K-P. Guenther3, W. Puhl4,
K. Dreinhoefer4. 1Nufﬁeld Department of Orthopaedic Surgery,
University of Oxford, UNITED KINGDOM, 2Department of Social
medicine, University of Bristol, UNITED KINGDOM, 3Universita¨tsklinikum
Carl Gustav Carus, Dresden, GERMANY, 4Department of Orthopaedics,
Ulm University, GERMANY
Purpose: Total hip joint replacement (THR) is a high volume, effective
but expensive and irreversible intervention, used to treat people with
advanced hip osteoarthritis (OA). In spite of over 40 years of experience
with THR, it is still unclear who should be referred for surgery, when in the
course of arthritis hip replacement should be carried out, or what the de-
terminants of relatively good or bad patient outcomes are. The ‘EUROHIP
consortium’, a multidisciplinary group of health care professionals from
20 centres in 12 European countries, is addressing these questions. As
part of its work, the consortium has developed a prospective cohort of
patients undergoing THR for primary OA. The purpose of this paper is
to describe the variations in disease severity in this cohort, explore the
relationships between clinical and radiographic measures of severity, and
explore some of the determinants of the variation.
Methods: A minimum of 50 consecutive, consenting patients coming
to THR in each participating orthopaedic centre within the EUROHIP
consortium were entered into the study. Baseline data collected included
demographics, employment and educational attainment (surrogates for
socio-economic status), current drug utilisation (a surrogate for co-
morbidities), involvement of other joints, and handedness. In addition,
each subject completed the WOMAC (Likert version 3.1) and the EQ5D
(EUROQoL) questionnaires. Data collected at the time of surgery in-
cluded the prosthesis used and ASA status. We attempted to obtain pre-
operative radiographs from all subjects. These were read by the same
two readers (PD and SW) using both Kellgren and Lawrence grading and
the OARSI atlas.
Results: Data from a total of 1327 subjects has been analysed. The mean
age of the group was 65.7 years, with a wide variation, and there were
more women (53.4%) than men. Most (79%) were ASA status 1 or 2, but
there was widespread use of medications, particularly for cardiovascular
disease and diabetes. Reported disease duration was relatively short,
being 5 years or less in 69.2%. Disease in other joint sites was common.
In 1051 of the 1327 subjects (79%) good quality radiographs were
available for reading and nearly all showed severe OA: the Kellgren and
Lawrence grade was 3 or 4 in 95.8%. However, there was much more
variation in severity assessed by the WOMAC, with many people having
relatively low scores. The mean total WOMAC score was 59.2 (SD 16.1).
